On February 4, 2021, ALJ Dee Lord issued a notice of initial determination
( ID ) in
Certain Wearable Monitoring Devices,
Systems, and Components Thereof (Inv. No. 337-TA-1190).
According to the notice, the ALJ found no violation of section
337.
By way of background, this investigation was based on a January
15, 2020 complaint filed by Philips North America, LLC and
Koninklijke Philips N.V. alleging violations of section 337 by
Respondents Fitbit, Inc., Garmin International, Inc. and Garmin 2
USA, Inc., Garmin Ltd. d/b/a Garmin Switzerland GmbH, Ingram Micro
Inc., Maintek Computer (Suzhou) Co., Ltd., and Inventec Appliances
(Pudong) through the importation and/or sale of certain wearable
https://www.afinalwarning.com/495234.html (Natural News) Rep. Katie Porter on Friday published a damning report revealing the devastating effects of Big Pharma mergers and acquisitions on U.S. healthcare, and recommending steps Congress should take to enact “comprehensive, urgent reform” of an integral part of a broken healthcare system.
(Article by Brett Wilkins republished from CommonDreams.org)
The report, entitled
While pharmaceutical executives often attempt to portray such consolidation as a means to increase operational efficiency, the report states that “digging a level deeper ‘exposes a troubling industry-wide trend of billions of dollars of corporate resources going toward acquiring other pharmaceutical corporations with patent-protected blockbuster drugs instead of putting those resources toward’ discovery of new drugs.”
January 1, 2021 marked the UK’s official separation from the EU and with that has come a raft of changes to how the nation will now do business with the rest of the world.
Many issues around free trade and the movement of goods and services have been well documented but details of how this will affect IP in the UK have grabbed fewer headlines.
Nevertheless, this issue is highly relevant as IP can underpin the value of businesses, especially in the pharmaceutical industry.
The
EU-UK Trade and Cooperation Agreement, which came into effect on January 1, outlines the ongoing relationship between the UK and EU and governs trade between EU member states and the UK. The Agreement includes a number of provisions relating to the protection and enforcement of IP rights, and specifies that such rights will continue to be protected to at least the standards required by the international treaties that the UK and EU are both parties to. We comment on som
To print this article, all you need is to be registered or login on Mondaq.com.
Up until now, the Danish Patent Office (Patent- og
Varemærkestyrelsen) has allowed SPC applications for
medicines based on a different medical use than the already
approved use of a medicinal product, considering the marketing
approval of the further medical use as the first
authorisation to place the product on the market for the
purposes of Article 3(d) of the SPC Regulation (EC 469/2009).
In view of the Santen decision from the CJEU (C-673/18), the
Danish Patent Office has now decided to discontinue this practice
Great news for Ecuador
The National Service of Intellectual
Property Rights (SENADI) confirmed the adoption of border
measures on the import of a container with more than 600,000
counterfeit goods of different marks, especially cell phone
accessories and packaging, which would have been ready to be
assembled and distributed across our country.
Customs in Manzanillo, Mexico, warned about the existence of a
container in transit, with Guayaquil as its final destination,
which contained suspicious goods corresponding to counterfeit goods
of the best-known cell phone marks. CorralRosales followed the container s
route, which included previous transit through Cartagena de
Indias-Colombia and the Port of Callao-Peru, constantly making sure